Percutaneous transplantation of human umbilical cord-derived mesenchymal stem cells in a dog suspected to have fibrocartilaginous embolic myelopathy.
10.4142/jvs.2013.14.4.495
- Author:
Wook Hun CHUNG
1
;
Seon Ah PARK
;
Jae Hoon LEE
;
Dai Jung CHUNG
;
Wo Jong YANG
;
Eun Hee KANG
;
Chi Bong CHOI
;
Hwa Seok CHANG
;
Dae Hyun KIM
;
Soo Han HWANG
;
Hoon HAN
;
Hwi Yool KIM
Author Information
1. Department of Veterinary Surgery, College of Veterinary Medicine, Konkuk University, Seoul 143-701, Korea. hykim@konkuk.ac.kr
- Publication Type:Case Reports ; Research Support, Non-U.S. Gov't
- Keywords:
dog;
fibrocartilaginous embolic myelopathy;
human umbilical cord-derived mesenchymal stem cells;
percutaneous transplantation;
xenotransplantaion
- MeSH:
Animals;
Cartilage Diseases/etiology/therapy/*veterinary;
*Cord Blood Stem Cell Transplantation/veterinary;
Dog Diseases/etiology/*therapy;
Dogs;
Embolism/etiology/therapy/*veterinary;
Female;
Humans;
Mesenchymal Stromal Cells/cytology/*metabolism;
Spinal Cord Diseases/etiology/therapy/*veterinary;
Treatment Outcome
- From:Journal of Veterinary Science
2013;14(4):495-497
- CountryRepublic of Korea
- Language:English
-
Abstract:
The use of human umbilical cord blood-derived mesenchymal stem cells for cell transplantation therapy holds great promise for repairing spinal cord injury. Here we report the first clinical trial transplantation of human umbilical cord (hUCB)-derived mesenchymal stem cells (MSCs) into the spinal cord of a dog suspected to have fibrocartilaginous embolic myelopathy (FCEM) and that experienced a loss of deep pain sensation. Locomotor functions improved following transplantation in a dog. Based on our findings, we suggest that transplantation of hUCB-derived MSCs will have beneficial therapeutic effects on FCEM patients lacking deep pain sensation.
